Epigenetic activation of E-cadherin is a candidate therapeutic target in human hepatocellular carcinoma

14Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

E-cadherin is a key cell adhesion molecule implicated in tumor suppression that is frequently altered in hepatocellular carcinoma (HCC), particularly in hepatitis B virus-related tumors. Here, we report that the epigenetic drugs 5-azacytidine and trichostatin A up-regulated E-cadherin expression in HCC cells. The depletion of DNMT1 restored E-cadherin expression via demethylation, whereas the depletion of DNMT3A or DNMT3B did not. Activated E-cadherin suppressed HCC cell colony formation. However, E-cadherin expression was repressed by HBx transfection due to the DNA methylation induced by the elevation of DNMT1 in the HCC cell lines. The present study indicates that E-cadherin expression is regulated by epigenetic agents in HCC cells, which suggests a schema for restoring E-cadherin by targeting its epigenetic mechanism.

Cite

CITATION STYLE

APA

Qiu, X., Qiao, F., Su, X., Zhao, Z., & Fan, H. (2010). Epigenetic activation of E-cadherin is a candidate therapeutic target in human hepatocellular carcinoma. Experimental and Therapeutic Medicine, 1(3), 519–523. https://doi.org/10.3892/etm_00000082

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free